Wafik S. El-Deiry: Very much looking forward to traveling and attending the 2024 WIN Consortium in Cancer Personalized Medicine Symposium in Abu Dhabi

Wafik S. El-Deiry shared on LinkedIn:

“Very much looking forward to traveling and attending the 2024 WIN Consortium in Cancer Personalized Medicine Symposium in Abu Dhabi in the coming days. Happy to see the weather is mostly sunny with temps between mid-60s to mid-70s.

Looking forward to meeting colleagues, friends, >300 attendees I’m aware of, listening, and learning from the world-class faculty. Grateful for the partnership with Burjeel Holdings, the WIN Symposium co-chairs and members of the organizing committee.”

View additional information.
Source: Wafik S. El-Deiry/LinkedIn

Wafik El-Deiry, MD, PhD, FACP, FRSM, an American Cancer Society Research Professor, is the Associate Dean for Oncologic Sciences at the Warren Alpert Medical School and Director of the Legorreta Cancer Center at Brown University. Dr. El-Deiry discovered p21(WAF1) as a p53 target gene, cell cycle inhibitor, and tumor suppressor that explained the mammalian cell stress response.

This has been the most highly cited original work published in Cell. He discovered TRAIL receptor DR5 as a p53 target, and ONC201/TIC10 as a TRAIL pathway, integrated stress response inducer, and cancer therapeutic with efficacy in diffuse midline glioma and other tumors.  He was named one of America’s Top Oncologists by the Consumer Res Council of America in 2008 and 2009. He is a practicing physician-scientist specializing in colorectal cancer treatment.